Finn
CORT Biotechnology · Commercial biotech · Cortisol modulators · Oncology launch · Thesis updated November 8, 2026

Oncology launch accelerates as core endocrine business finds new life

01 Running thesis

Diversification is finally real

Corcept used to be almost entirely dependent on Korlym. That made the company simple to understand but fragile. In March 2026, the FDA approved Lifyorli for platinum-resistant ovarian cancer, and Corcept began selling it in April. That turns Corcept from a Cushing's syndrome company into a commercial business with two distinct growing franchises.

The Lifyorli launch continues to exceed expectations. In the third quarter of 2026, the drug generated $91.4 million in revenue, a 92 percent sequential jump. More than 2,300 patients have started treatment, and prescriptions show early signs of expanding into earlier lines of therapy. This rapid adoption validates the company's expansion into oncology.

The bull case is that Lifyorli continues to ramp quickly, while the legacy endocrine business benefits from new medical guidelines. In October 2026, the American Diabetes Association recommended hypercortisolism screening for difficult-to-treat diabetes. This significantly expands the potential patient pool for Korlym and, if approved on its December 17, 2026 target date, relacorilant.

The bear case remains serious. Korlym faces certain generic pressure after Corcept exhausted its Teva patent appeals in July 2026. Selling and administrative spending jumped to support the new launches. If Lifyorli sales momentum stalls in earlier lines of therapy or the FDA rejects relacorilant again, the company could struggle to offset the eventual decline of its core business.

Nov 2026▲Q3 2026 results showed Lifyorli revenue jumping 92 percent sequentially to $91.4 million. The American Diabetes Association also recommended hypercortisolism screening for difficult-to-treat diabetes, expanding the potential endocrine market.
Jul 2026▲Management raised full-year 2026 revenue guidance to $1.1 billion to $1.2 billion following strong Q2 results. Lifyorli generated $47.6 million in its first quarter, and the Korlym franchise stabilized at $208.6 million.
Jul 2026→The U.S. Court of Appeals denied Corcept's petition for a rehearing on the Teva patent litigation. The FDA also assigned a December 17, 2026 target date for the relacorilant Cushing's review.
Jun 2026▲Corcept resubmitted the relacorilant NDA for Cushing's syndrome after the FDA's December 2025 rejection. This gives the program a clearer path and likely shifts the next major readout to the FDA review cycle.
Apr 2026▲Management raised early 2026 revenue guidance to $950 million to $1.05 billion. Early Lifyorli adoption was strong, with prescriptions from over 200 physicians in the first 36 days.
Apr 2026→Q1 2026 revenue rose to $164.9 million, but SG&A rose sharply to support commercialization. Korlym prescriptions hit records, while insurance and pharmacy backlogs delayed some revenue recognition.
Feb 2026▼The 2025 10-K captured two major hits: the FDA rejected relacorilant for Cushing's syndrome, and Corcept lost its final Teva patent appeal. The positive offset was strong ovarian cancer data for relacorilant.
02 Business model

Specialty drugs fund the pipeline

Corcept makes money by selling specialty medicines in the United States. Korlym and its authorized generic treat high blood sugar in adults with endogenous Cushing's syndrome. Lifyorli, which uses the same active drug as relacorilant, is sold with nab-paclitaxel for certain ovarian cancer patients.

The company relies on cash flow from the established Korlym franchise and the new Lifyorli launch to fund an R&D pipeline of selective cortisol modulators. In the third quarter of 2026, Korlym generated a record $249.1 million while Lifyorli added $91.4 million. Driven by this dual strength, management expects full-year 2026 revenue between $1.1 billion and $1.2 billion.

The model works best when specialty pharmacies, insurers, and doctors move patients through the system quickly. Corcept recently resolved prior authorization and pharmacy transition backlogs, clearing the way to capture strong underlying demand in the endocrine business.

Costs are rising with the bigger ambition. Selling, general, and administrative expenses increased significantly in 2026 to support commercialization. That spending is sensible if both launches work, but painful if either one misses.

03 Product portfolio

Korlym pays, Lifyorli grows

Cash cow

Korlym

Korlym treats hyperglycemia in adult patients with endogenous Cushing's syndrome. It remains the main revenue base, but it faces generic pressure.

Steady

Authorized generic Korlym

Corcept launched an authorized generic in June 2024. It helps defend volume, but it also lowers average selling price.

Growth engine

Lifyorli

Lifyorli was approved in March 2026 for certain platinum-resistant ovarian cancer patients. It generated $91.4 million in the third quarter of 2026.

Option

Relacorilant for Cushing's syndrome

Corcept resubmitted the application in June 2026 after a previous rejection. The FDA set a target action date of December 17, 2026.

Option

Miricorilant for MASH

Miricorilant is moving into a Phase 2 trial for daily dosing after showing a 19.2 percent improvement in liver fibrosis in a previous study.

Option

Dazucorilant for ALS

Dazucorilant is planned for a pivotal Phase 3 trial in ALS in 2026. This is a high-risk neurology program.

Option

Nenocorilant in oncology

Nenocorilant is being tested with nivolumab in the Phase 1b SYNERGY trial for solid tumors. It is part of Corcept's broader bet on cortisol modulation in cancer.

04 Business segments

One reported segment, two markets

Endocrinology73%modest
Oncology27%growing fast

Corcept operates as a single business segment. In Q3 2026, the company generated $249.1 million from endocrinology products and $91.4 million from the newly launched oncology product, Lifyorli.

05 Risk factors

What can break the story

Korlym generic erosion

High impact · High odds

Corcept lost its final Teva patent appeal in July 2026 when the court denied a rehearing. That finalizes the loss of patent protection and solidifies the long-term threat of revenue and margin erosion from generic entrants.

We watchTrack Korlym volume, average price, and any new generic launch disclosures.

Lifyorli ramp stalls

High impact · Medium odds

Lifyorli started strong with over 2,300 patients by Q3 2026. The next test is moving into earlier lines of therapy. If late-line patients exhaust and earlier adoption proves commercially difficult, Lifyorli may not offset Korlym pressure.

We watchWatch upcoming quarterly Lifyorli sales and commentary on earlier lines of therapy.

Cushing's regulatory setback

High impact · Medium odds

The FDA is reviewing the relacorilant resubmission for Cushing's syndrome with a December 17, 2026 target date. A second rejection would permanently impair the endocrine pipeline.

We watchWatch for the FDA decision on the December action date.

Launch spending outruns revenue

Medium impact · Medium odds

Operating expenses are rising to support the Lifyorli and hypercortisolism launches. If sales do not ramp fast enough to cover these costs, profits and cash flow could stay under pressure.

We watchCompare quarterly revenue growth against SG&A and R&D spending.

Legal overhang

Medium impact · Medium odds

Corcept faces an antitrust lawsuit from Teva scheduled for a March 2027 trial. The company is also dealing with a securities class action. These cases can cost money, take management time, and hurt investor trust.

We watchWatch court filings, settlement talks, and any reserve or expense disclosure in filings.
06 Research standards

Sources and research notes

This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.

Thesis reviewed
November 8, 2026
Score data
November 15, 2026
Reviewed by
Shivam Bharuka
  1. Corcept Q3 2026 earnings transcript
  2. Corcept Q2 2026 Form 10-Q
  3. Corcept Q1 2026 Form 10-Q
07 Explore the industry

Comparable Biotechnology companies

Companies near Corcept Therapeutics Incorporated in Finn's Biotechnology industry ranking.

Get started with Finn today